TrialAutopsyBuilt by Jawad Momani (Pwnedl0l)

Autopsy report · NCT03150056

Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy in Participants With Castrate-resistant Prostate Cancer

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.
“This study has been terminated due to meeting protocol defined futility.”

The sponsor’s own words in the registry.

Life of this trial

201720182019202020212022Registered2017-05-09Started2017-07-18Primary completion2020-07-31Stopped2021-06-22Results posted2021-08-26

Vital statistics

Status
Terminated
Phase
Phase 1
Sponsor
GlaxoSmithKline
Sponsor type
Industry
Conditions
Solid Tumours
Interventions
GSK525762; Abiraterone; Enzalutamide; Prednisone
Participants
73
Sites
20
Countries
Australia, Spain, United Kingdom, United States

Trials that died the same way

Look deeper

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.